| 000 | 01077 a2200289 4500 | ||
|---|---|---|---|
| 005 | 20250517130139.0 | ||
| 264 | 0 | _c20190508 | |
| 008 | 201905s 0 0 eng d | ||
| 022 | _a1527-7755 | ||
| 024 | 7 |
_a10.1200/JCO.2016.70.7463 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSohal, Davendra P S | |
| 245 | 0 | 0 |
_aReply to A. Wang-Gillam et al. _h[electronic resource] |
| 260 |
_bJournal of clinical oncology : official journal of the American Society of Clinical Oncology _c02 2017 |
||
| 300 |
_a690-691 p. _bdigital |
||
| 500 | _aPublication Type: Letter; Comment | ||
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aIrinotecan |
| 650 | 0 | 4 | _aNeoplasms, Second Primary |
| 650 | 0 | 4 | _aPancreatic Neoplasms |
| 650 | 0 | 4 | _aTopoisomerase I Inhibitors |
| 700 | 1 | _aMangu, Pamela B | |
| 700 | 1 | _aLaheru, Daniel | |
| 700 | 1 | _aKhorana, Alok A | |
| 773 | 0 |
_tJournal of clinical oncology : official journal of the American Society of Clinical Oncology _gvol. 35 _gno. 6 _gp. 690-691 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1200/JCO.2016.70.7463 _zAvailable from publisher's website |
| 999 |
_c26667516 _d26667516 |
||